Pharmaron Beijing Co., Ltd. (HKG: 3759)

Market Cap	49.23B
Revenue (ttm)	13.06B
Net Income (ttm)	2.09B
Shares Out	n/a
EPS (ttm)	1.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Jun 27, 2024

Volume	6,325,292
Open	14.18
Previous Close	14.16
Day's Range	13.74 - 14.36
52-Week Range	7.98 - 24.85
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 27, 2025

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. The company offers laboratory chemistry services, including medicinal and synthetic chemistry, chemistry for new modalities, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, and computer-aided drug design; bioscience services, such as structural biology, in vi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 20,295
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3759

Financial Performance

In 2023, Pharmaron Beijing's revenue was 11.54 billion, an increase of 12.39% compared to the previous year's 10.27 billion. Earnings were 1.60 billion, an increase of 16.48%.

Financial numbers in CNY